Literature DB >> 9465977

Standardizing the expression and nomenclature of cancer treatment regimens. American Society of Health-System Pharmacist (ASHP), American Medical Association (AMA), American Nurses Association (ANA).

D R Kohler1, M J Montello, L Green, C Huntley, J L High, A Fallavollita, B R Goldspiel.   

Abstract

Guidelines for describing cancer chemotherapy regimens in all aspects of drug development, including treatment protocols, order forms, and product labels, are proposed. To complement the approaches to reducing medication errors that have been recommended by ASHP and others, pharmacists at the National Institutes of Health and the National Cancer Institute, with the input of oncology pharmacists from diverse areas of practice, developed guidelines for expressing chemotherapy dosage schedules and treatment regimens. The guidelines present standards that are broadly applicable and can be adopted by other institutions. Clear and unambiguous expression of all medication orders and consistency of treatment descriptions are suggested. Written treatment plans and orders should contain enough information to allow health care providers from diverse disciplines to compare them with published treatment descriptions and investigational protocols and must therefore include planned dosages and schedules expressed in patient-specific units. In general, drug dosages should be expressed as the amount of drug administered from a single container. When ordering drugs that are part of complex or combination-drug regimens, prescribers should write as many of the orders at one time as is possible, so that continuity might be preserved. Standard rules are proposed for describing chemotherapy regimens.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9465977     DOI: 10.1093/ajhp/55.2.137

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  7 in total

1.  Implementing a multiple-isolator unit for centralized preparation of cytotoxic drugs in a cancer center pharmacy.

Authors:  J L Cazin; P Gosselin
Journal:  Pharm World Sci       Date:  1999-08

2.  Analysis and quantification of prescribing and transcription errors in a paediatric oncology service.

Authors:  R Pichon; G L Zelger; P Wacker; A L Vodoz; J Humbert
Journal:  Pharm World Sci       Date:  2002-02

3.  Program to support safe administration of oral chemotherapy.

Authors:  Ann M Birner; Marilyn K Bedell; Jean T Avery; Marc S Ernstoff
Journal:  J Oncol Pract       Date:  2006-01       Impact factor: 3.840

Review 4.  Computerized prescriber order entry in the outpatient oncology setting: from evidence to meaningful use.

Authors:  V Kukreti; R Cosby; A Cheung; S Lankshear
Journal:  Curr Oncol       Date:  2014-08       Impact factor: 3.677

5.  Improvement of Chemotherapy Solutions Production Procedure in a Hospital Central Chemotherapy Preparation Unit: A Systematic Risk Assessment to Prevent Avoidable Harm in Cancer Patients.

Authors:  Klio Bourika; Angelos Koutras; Haralambos Kalofonos; Anna Vicha; Ekaterini Tsiata; Evangelia Papadimitriou; Konstantinos Avgoustakis; Zoi Panagi
Journal:  Clin Med Insights Oncol       Date:  2019-06-10

6.  Pharmacoeconomic effect of compliance with pharmacist's intervention based on cancer chemotherapy regimens: a cohort study.

Authors:  Makoto Hayashi; Akimasa Yamatani; Hiromu Funaki; Kenichi Miyamoto
Journal:  J Pharm Health Care Sci       Date:  2015-03-05

Review 7.  Identifying options for oncology therapy regimen codification to improve standardization-combined results of an expert panel and a review.

Authors:  Robert Terkola; Christophe Bardin; Garbiñe Lizeaga Cundin; Nadine Zeinab; Mirjam Crul
Journal:  J Clin Pharm Ther       Date:  2021-03-09       Impact factor: 2.512

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.